高度无球的镜片对象眼镜对儿童的附加效应,这些儿童在不充分控制的阿特罗平单一疗法下得到控制
Bryan Xiangrong Sim1,2, Kai Lyn Loh1,2, Hla Myint Htoon3
1Singapore National Eye Centre (SNEC), Singapore.
Ophthalmology science
|April 18, 2025
概括
结合控制近视的眼镜镜片与高非球性镜片准 (HALT) 技术和氨酸,在仅用低剂量氨酸 (LDA) 控制不良的儿童中显著减缓了近视进展.
科学领域:
- 眼科医生 眼科 眼科
- 儿科光学测量 儿科光学测量
- 近视控制研究近视研究
背景情况:
- 儿童近视的进展,特别是在东亚,是一个重大的公共卫生挑战.
- 低剂量氨酸 (LDA) 是一种常见的治疗方法,但尽管使用LDA,但一些儿童仍在继续取得进展.
- 需要有效的策略来管理儿童群体中渐进的近视.
研究的目的:
- 评估高非球性镜片目标 (HALT) 眼镜镜片与LDA结合在持续近视进展的儿童中的疗效.
- 评估HALT透镜和氨酸在管理具有挑战性的儿科近视病例中的协同效应.
主要方法:
- 一项前性队列研究包括6至11岁的儿童,在6个月的LDA中至少有0.5个二光度 (D) 的近视进展.
- 参与者在使用HALT (Essilor Stellest) 眼镜镜片的同时继续接受LDA治疗.
- 在治疗开始后的6-12个月内,对球体等值 (SE) 和轴长 (AL) 进行了监测.
主要成果:
- 组合治疗减缓了近视的进展,在6个月后降至-0.06D/0.06毫米,在12个月后降至-0.15D/0.14毫米.
- 在24%的儿童中观察到AL的高视度转移.
- 年龄较小和瞳孔尺寸较小 (可能表明遵守或吸收不良) 与持续的进展有关.
结论:
- 在LDA治疗中添加HALT眼镜镜片显著减少了6-11岁儿童近视的进展.
- 组合疗法显示出潜在的协同效应,支持其用于具有挑战性的近视病例.
- 这种方法提供了一个有前途的策略,用于管理儿科近视进展不响应单独LDA.
相关概念视频
Open Angle Glaucoma: Treatment
358
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
358
Angle Closure Glaucoma: Treatment
374
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
374
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
557
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
557
Focusing of Light in the Eye
1.5K
Light rays enter the eye through the cornea, a transparent dome-shaped tissue that is the eye's outermost layer. The cornea bends or refracts, light rays traveling to the pupil. The shape of the cornea determines how much of the light is bent and whether the image will be focused correctly on the retina at the back of the eye. Once the light has passed through both refraction layers, it converges into a single focal point onto a small area. This is where photoreceptors start transforming...
1.5K
Direct-Acting Cholinergic Agonists: Therapeutic Uses
615
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
615
Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.1K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.1K


